Return on Equity: The amount of net income returned as a percentage of shareholders equity. Return on equity measures a corporation's profitability by revealing how much profit a company generates with the money shareholders have invested. Calculated as: Income from Continuing Operations / Total Common Equity
Spyre Therapeutics, Inc. (SYRE) had Return on Equity of -13.40% for the most recently reported fiscal quarter, ending 2026-03-31.
| Income Statement Financials | |
-- |
|
$-69.00M |
|
-- |
|
-- |
|
$45.64M |
|
$-45.64M |
|
$-23.36M |
|
$-69.00M |
|
$-69.00M |
|
$-69.00M |
|
$-69.00M |
|
$-69.00M |
|
$-69.00M |
|
$-45.64M |
|
$-45.64M |
|
78.55M |
|
78.55M |
|
$-0.74 |
|
$-0.74 |
|
| Balance Sheet Financials | |
$763.95M |
|
-- |
|
-- |
|
$763.95M |
|
$85.16M |
|
-- |
|
$7.98M |
|
$93.14M |
|
$514.99M |
|
$670.81M |
|
$670.81M |
|
78.84M |
|
| Cash Flow Statement Financials | |
$-57.37M |
|
$56.58M |
|
$12.26M |
|
$85.72M |
|
$97.19M |
|
$11.46M |
|
$12.81M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
8.97 |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
$-57.37M |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
|
Return on Equity |
-13.40% |
-10.29% |
|
-9.03% |
|
-10.29% |
|
$8.51 |
|
$-0.73 |
|
$-0.73 |
|